Clinical trial NCT00033384 (phase 2, status: completed)
Conditions: breast cancer, colorectal cancer, lung cancer, pancreatic cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C25.3
Drugs: ci-1040
SMILES: OC(=NOCC1CC1)C1=C(NC2=C(Cl)C=C(I)C=C2)C(F)=C(F)C=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed metastatic or inoperable non-small cell
             lung, breast, or colon cancer or duct cell carcinoma of the exocrine pancreas

          -  Bidimensionally measurable lesions that are not previously irradiated

               -  New lesions that have developed in a previously irradiated field may be used as
                  measurable disease

          -  No brain metastases

               -  Patients with prior brain metastases are allowed provided they have undergone
                  prior resection of metastases and/or 1 prior course of cranial irradiation, have
                  no new sites of brain metastases since then, have no worsening CNS symptoms, and
                  have discontinued prior corticosteroids for at least 30 days

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Sex:

          -  Not specified

        Menopausal status:

          -  Not specified

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 2 times upper limit of normal (ULN)

          -  AST or ALT no greater than 2 times ULN (5 times ULN if due to liver involvement)

        Renal:

          -  Creatinine no greater than 1.5 times ULN

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 30 days after study
             participation

          -  Capable of swallowing intact study medication capsules

          -  Capable of following instructions regarding study medication or has daily caregiver to
             administer study medication

          -  No concurrent serious infection

          -  No life-threatening illness unrelated to tumor

          -  No other prior or concurrent malignancy within the past 3 years except nonmelanoma
             skin cancer or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 2 weeks since prior immunotherapy or biologic therapy

        Chemotherapy:

          -  At least 4 weeks since prior cytotoxic chemotherapy

          -  No more than 1 prior cytotoxic chemotherapy regimen for metastatic non-small cell lung
             or colon cancer

          -  No more than 2 prior cytotoxic chemotherapy regimens for breast cancer

          -  No prior cytotoxic chemotherapy for pancreatic cancer

        Endocrine therapy:

          -  See Disease Characteristics

          -  At least 2 weeks since other prior hormonal therapy

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 3 weeks since prior radiotherapy and recovered

          -  No concurrent radiotherapy

        Surgery:

          -  See Disease Characteristics

        Other:

          -  No other concurrent anticancer agents